| Name | Title | Contact Details |
|---|
As a nonprofit engineering innovation company, Draper serves our nation`s interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers` needs and to deliver new capabilities to them.
Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics' goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values.
At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions. Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don`t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
ZielBio is an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes. Our proprietary drug discovery platform Zielfind™ combines the power of functional, high throughput screening with large content data analytics to identify high value targets. We have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind™.